Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy (SMA)

CORAL GABLES, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
November 08, 2017 16:41 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
November 01, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017

CORAL GABLES, Fla., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
October 31, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

-- Top-Line Results Expected in Early December -- -- Required Abuse Liability Studies Completed -- CORAL GABLES, Fla., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,...
October 16, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum

CORAL GABLES, Fla., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
August 30, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities

-- FDA grants Special Protocol Assessment agreement for Phase 3 MuSK-MG trial -- -- Enrollment for second Phase 3 trial for LEMS nearing completion -- -- Expected NDA submission for Firdapse moves...
August 09, 2017 16:29 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
August 01, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017

CORAL GABLES, Fla., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
June 26, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Joins Russell 3000 Index

CORAL GABLES, Fla., June 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
June 01, 2017 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference

CORAL GABLES, Fla., June 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...